Taprenepag
CAS: 752187-80-7
Ref. 3D-CFB18780
| 5mg | To inquire | ||
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire | ||
| 100mg | To inquire |
Product Information
Taprenepag is a prodrug that is hydrolyzed to its active form, the camphor derivative, in the body. Camphor derivatives are a class of compounds that are used as drugs and have been shown to have anticancer activity. Taprenepag has been shown to inhibit the growth of cervical cancer cells by binding to response element-binding protein (RBP) and inhibiting cell proliferation. It also inhibits angiogenic factors such as vascular endothelial growth factor (VEGF) and erythropoietin (EPO), which are involved in tumor growth. The compound also inhibits PI3K/Akt/mTOR signaling pathway, which may contribute to its anti-cancer activity. Taprenepag has been shown to be effective in models of bowel disease, such as inflammatory bowel disease and ulcerative colitis. In addition, this drug has been studied for use in skin cancer treatment with benzalkonium chloride.
Chemical properties
Technical inquiry about: 3D-CFB18780 Taprenepag
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
